Meeting
2023 ASCO Genitourinary Cancers Symposium
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
Authors
Nazli Dizman
Yale University School of Medicine, New Haven, CT
Nazli Dizman , Ameish Govindarajan , Zeynep Busra Zengin , Luis A Meza , Nishita Tripathi , Nicolas Sayegh , Daniela V. Castro , Elyse H. Chan , Kyle O. Lee , Sweta R. Prajapati , Matthew I. Feng , Vivian Loo , Makala Pace , Shea O'brien , Erin B. Bailey , Regina Barragan-Carrillo , Alex Chehrazi-Raffle , Xiaochen Li , Neeraj Agarwal , Sumanta Monty Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 678)
DOI
10.1200/JCO.2023.41.6_suppl.678
Abstract #
678
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento